Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025
Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on FDA-approved dermatological treatments, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.
The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. U.S. participants can dial 1-866-777-2509, while international callers should use 1-412-317-5413. The webcast will be available on Journey Medical's website for approximately 30 days following the call.
Journey Medical Corporation (NASDAQ:DERM), un'azienda farmaceutica in fase commerciale specializzata in trattamenti dermatologici approvati dalla FDA, ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per il 12 agosto 2025, dopo la chiusura del mercato.
La società terrà una conference call e una trasmissione audio in webcast alle 16:30 ET dello stesso giorno. I partecipanti dagli Stati Uniti possono chiamare il numero 1-866-777-2509, mentre i chiamanti internazionali dovranno utilizzare il numero 1-412-317-5413. Il webcast sarà disponibile sul sito web di Journey Medical per circa 30 giorni dopo la chiamata.
Journey Medical Corporation (NASDAQ:DERM), una empresa farmacéutica en etapa comercial centrada en tratamientos dermatológicos aprobados por la FDA, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el 12 de agosto de 2025, después del cierre del mercado.
La compañía realizará una conferencia telefónica y una transmisión de audio en webcast a las 4:30 p.m. ET del mismo día. Los participantes en EE. UU. pueden llamar al 1-866-777-2509, mientras que los llamantes internacionales deben usar el 1-412-317-5413. El webcast estará disponible en el sitio web de Journey Medical durante aproximadamente 30 días después de la llamada.
Journey Medical Corporation (NASDAQ:DERM)은 FDA 승인 피부과 치료에 중점을 둔 상업 단계 제약 회사로, 2025년 2분기 재무 결과 발표를 2025년 8월 12일 장 마감 후에 예정하고 있습니다.
회사는 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 오디오 웹캐스트를 진행할 예정입니다. 미국 내 참여자는 1-866-777-2509로 전화할 수 있으며, 국제 전화는 1-412-317-5413을 이용해야 합니다. 웹캐스트는 콜 후 약 30일간 Journey Medical 웹사이트에서 시청 가능합니다.
Journey Medical Corporation (NASDAQ:DERM), une entreprise pharmaceutique en phase commerciale spécialisée dans les traitements dermatologiques approuvés par la FDA, a prévu d’annoncer ses résultats financiers du deuxième trimestre 2025 le 12 août 2025, après la clôture du marché.
La société organisera une conférence téléphonique et une diffusion audio en webcast à 16h30 ET le même jour. Les participants américains peuvent appeler le 1-866-777-2509, tandis que les appelants internationaux doivent composer le 1-412-317-5413. Le webcast sera disponible sur le site web de Journey Medical pendant environ 30 jours après l’appel.
Journey Medical Corporation (NASDAQ:DERM), ein pharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf von der FDA zugelassene dermatologische Behandlungen, hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für den 12. August 2025 nach Börsenschluss geplant.
Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz und eine Audio-Webcast veranstalten. Teilnehmer aus den USA können die Nummer 1-866-777-2509 wählen, internationale Anrufer sollten 1-412-317-5413 verwenden. Der Webcast wird auf der Website von Journey Medical etwa 30 Tage nach dem Anruf verfügbar sein.
- None.
- None.
Company to host conference call to discuss financial results and provide a corporate update on August 12, 2025 at 4:30 p.m. ET
SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025 financial results after the U.S. financial markets close on Tuesday, August 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Tuesday, August 12, 2025 at 4:30 p.m. ET.
To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international). All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to join the Journey Medical conference call. Participants can register for the conference by navigating to https://dpregister.com/sreg/10201702/ffa49f90a2. Please note that registered participants will receive their dial-in number upon registration.
A live audio webcast can be accessed on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, and will remain available for replay for approximately 30 days after the conference call.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight FDA-approved prescription drugs for dermatological conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When will Journey Medical (DERM) release Q2 2025 earnings?
How can investors join Journey Medical's Q2 2025 earnings call?
Where can I access the webcast of Journey Medical's Q2 earnings call?
What is Journey Medical's (DERM) main business focus?
